nodes	percent_of_prediction	percent_of_DWPC	metapath
Alprostadil—ABCC5—Zidovudine—acquired immunodeficiency syndrome	0.33	0.54	CbGbCtD
Alprostadil—ABCC4—Zidovudine—acquired immunodeficiency syndrome	0.159	0.259	CbGbCtD
Alprostadil—ABCC4—Lamivudine—acquired immunodeficiency syndrome	0.123	0.201	CbGbCtD
Alprostadil—PTGIR—endothelium—acquired immunodeficiency syndrome	0.00534	0.064	CbGeAlD
Alprostadil—PTGIR—blood plasma—acquired immunodeficiency syndrome	0.00474	0.0568	CbGeAlD
Alprostadil—SLCO2A1—Transport of organic anions—ALB—acquired immunodeficiency syndrome	0.00309	0.0645	CbGpPWpGaD
Alprostadil—PTGER2—blood—acquired immunodeficiency syndrome	0.00296	0.0355	CbGeAlD
Alprostadil—SLCO3A1—Transport of organic anions—ALB—acquired immunodeficiency syndrome	0.00293	0.0611	CbGpPWpGaD
Alprostadil—PTGER2—bone marrow—acquired immunodeficiency syndrome	0.00287	0.0344	CbGeAlD
Alprostadil—PTGER2—vagina—acquired immunodeficiency syndrome	0.00275	0.0329	CbGeAlD
Alprostadil—ABCC4—blood plasma—acquired immunodeficiency syndrome	0.00263	0.0315	CbGeAlD
Alprostadil—PTGER2—lung—acquired immunodeficiency syndrome	0.0026	0.0312	CbGeAlD
Alprostadil—SLCO3A1—retina—acquired immunodeficiency syndrome	0.00229	0.0275	CbGeAlD
Alprostadil—PTGER1—nervous system—acquired immunodeficiency syndrome	0.00228	0.0274	CbGeAlD
Alprostadil—PTGER1—central nervous system—acquired immunodeficiency syndrome	0.0022	0.0263	CbGeAlD
Alprostadil—ABCC5—retina—acquired immunodeficiency syndrome	0.00207	0.0249	CbGeAlD
Alprostadil—SLCO2A1—skin of body—acquired immunodeficiency syndrome	0.00199	0.0239	CbGeAlD
Alprostadil—PTGIR—digestive system—acquired immunodeficiency syndrome	0.00182	0.0218	CbGeAlD
Alprostadil—PTGER2—lymph node—acquired immunodeficiency syndrome	0.00178	0.0213	CbGeAlD
Alprostadil—PTGIR—blood—acquired immunodeficiency syndrome	0.00174	0.0208	CbGeAlD
Alprostadil—SLCO2B1—Transport of organic anions—ALB—acquired immunodeficiency syndrome	0.0017	0.0355	CbGpPWpGaD
Alprostadil—PTGIR—spinal cord—acquired immunodeficiency syndrome	0.00167	0.0201	CbGeAlD
Alprostadil—SLCO3A1—blood—acquired immunodeficiency syndrome	0.00153	0.0184	CbGeAlD
Alprostadil—PTGIR—lung—acquired immunodeficiency syndrome	0.00152	0.0182	CbGeAlD
Alprostadil—SLCO3A1—spinal cord—acquired immunodeficiency syndrome	0.00148	0.0177	CbGeAlD
Alprostadil—SLCO3A1—vagina—acquired immunodeficiency syndrome	0.00142	0.017	CbGeAlD
Alprostadil—PTGIR—nervous system—acquired immunodeficiency syndrome	0.00141	0.0169	CbGeAlD
Alprostadil—SLCO2A1—vagina—acquired immunodeficiency syndrome	0.00141	0.0169	CbGeAlD
Alprostadil—PTGIR—central nervous system—acquired immunodeficiency syndrome	0.00136	0.0163	CbGeAlD
Alprostadil—SLCO3A1—lung—acquired immunodeficiency syndrome	0.00134	0.0161	CbGeAlD
Alprostadil—ABCC5—bone marrow—acquired immunodeficiency syndrome	0.00134	0.0161	CbGeAlD
Alprostadil—SLCO2A1—lung—acquired immunodeficiency syndrome	0.00133	0.0159	CbGeAlD
Alprostadil—ABCC5—vagina—acquired immunodeficiency syndrome	0.00129	0.0154	CbGeAlD
Alprostadil—SLCO3A1—nervous system—acquired immunodeficiency syndrome	0.00124	0.0149	CbGeAlD
Alprostadil—PTGER2—Class A/1 (Rhodopsin-like receptors)—CCL3L1—acquired immunodeficiency syndrome	0.00123	0.0258	CbGpPWpGaD
Alprostadil—SLCO2A1—nervous system—acquired immunodeficiency syndrome	0.00123	0.0148	CbGeAlD
Alprostadil—ABCC5—lung—acquired immunodeficiency syndrome	0.00122	0.0146	CbGeAlD
Alprostadil—SLCO3A1—central nervous system—acquired immunodeficiency syndrome	0.0012	0.0144	CbGeAlD
Alprostadil—SLCO2A1—central nervous system—acquired immunodeficiency syndrome	0.00119	0.0142	CbGeAlD
Alprostadil—SLCO2A1—Transport of vitamins, nucleosides, and related molecules—ALB—acquired immunodeficiency syndrome	0.00115	0.0239	CbGpPWpGaD
Alprostadil—SLCO2B1—digestive system—acquired immunodeficiency syndrome	0.00114	0.0137	CbGeAlD
Alprostadil—SLCO3A1—Transport of vitamins, nucleosides, and related molecules—ALB—acquired immunodeficiency syndrome	0.00109	0.0227	CbGpPWpGaD
Alprostadil—PTGIR—brain—acquired immunodeficiency syndrome	0.00108	0.0129	CbGeAlD
Alprostadil—SLCO2B1—spinal cord—acquired immunodeficiency syndrome	0.00105	0.0125	CbGeAlD
Alprostadil—PTGIR—lymph node—acquired immunodeficiency syndrome	0.00104	0.0125	CbGeAlD
Alprostadil—ABCC4—digestive system—acquired immunodeficiency syndrome	0.00101	0.0121	CbGeAlD
Alprostadil—ABCC4—blood—acquired immunodeficiency syndrome	0.000962	0.0115	CbGeAlD
Alprostadil—SLCO2B1—lung—acquired immunodeficiency syndrome	0.000952	0.0114	CbGeAlD
Alprostadil—SLCO3A1—brain—acquired immunodeficiency syndrome	0.000951	0.0114	CbGeAlD
Alprostadil—SLCO2A1—brain—acquired immunodeficiency syndrome	0.000942	0.0113	CbGeAlD
Alprostadil—PTGER2—GPCR ligand binding—CCL3L1—acquired immunodeficiency syndrome	0.00094	0.0196	CbGpPWpGaD
Alprostadil—ABCC4—bone marrow—acquired immunodeficiency syndrome	0.000931	0.0112	CbGeAlD
Alprostadil—SLCO3A1—lymph node—acquired immunodeficiency syndrome	0.000919	0.011	CbGeAlD
Alprostadil—SLCO2A1—lymph node—acquired immunodeficiency syndrome	0.00091	0.0109	CbGeAlD
Alprostadil—SLCO2B1—nervous system—acquired immunodeficiency syndrome	0.000882	0.0106	CbGeAlD
Alprostadil—ABCC5—brain—acquired immunodeficiency syndrome	0.000861	0.0103	CbGeAlD
Alprostadil—SLCO2B1—central nervous system—acquired immunodeficiency syndrome	0.000849	0.0102	CbGeAlD
Alprostadil—ABCC4—lung—acquired immunodeficiency syndrome	0.000843	0.0101	CbGeAlD
Alprostadil—PTGIR—Class A/1 (Rhodopsin-like receptors)—CCL3L1—acquired immunodeficiency syndrome	0.000834	0.0174	CbGpPWpGaD
Alprostadil—PTGER1—Class A/1 (Rhodopsin-like receptors)—CCL3L1—acquired immunodeficiency syndrome	0.000834	0.0174	CbGpPWpGaD
Alprostadil—ABCC5—lymph node—acquired immunodeficiency syndrome	0.000832	0.00998	CbGeAlD
Alprostadil—ABCC4—nervous system—acquired immunodeficiency syndrome	0.000781	0.00936	CbGeAlD
Alprostadil—ABCC4—central nervous system—acquired immunodeficiency syndrome	0.000752	0.00902	CbGeAlD
Alprostadil—PTGER2—Class A/1 (Rhodopsin-like receptors)—ACKR1—acquired immunodeficiency syndrome	0.000748	0.0156	CbGpPWpGaD
Alprostadil—PTGER2—Class A/1 (Rhodopsin-like receptors)—CCL4—acquired immunodeficiency syndrome	0.000676	0.0141	CbGpPWpGaD
Alprostadil—SLCO2B1—brain—acquired immunodeficiency syndrome	0.000674	0.00808	CbGeAlD
Alprostadil—SLCO2B1—lymph node—acquired immunodeficiency syndrome	0.000651	0.00781	CbGeAlD
Alprostadil—PTGIR—GPCR ligand binding—CCL3L1—acquired immunodeficiency syndrome	0.000635	0.0133	CbGpPWpGaD
Alprostadil—PTGER1—GPCR ligand binding—CCL3L1—acquired immunodeficiency syndrome	0.000635	0.0133	CbGpPWpGaD
Alprostadil—SLCO2B1—Transport of vitamins, nucleosides, and related molecules—ALB—acquired immunodeficiency syndrome	0.00063	0.0132	CbGpPWpGaD
Alprostadil—ABCC4—brain—acquired immunodeficiency syndrome	0.000597	0.00716	CbGeAlD
Alprostadil—ABCC4—lymph node—acquired immunodeficiency syndrome	0.000577	0.00692	CbGeAlD
Alprostadil—PTGER2—GPCR ligand binding—ACKR1—acquired immunodeficiency syndrome	0.00057	0.0119	CbGpPWpGaD
Alprostadil—PTGER2—GPCR ligand binding—CCL4—acquired immunodeficiency syndrome	0.000515	0.0108	CbGpPWpGaD
Alprostadil—PTGIR—Class A/1 (Rhodopsin-like receptors)—ACKR1—acquired immunodeficiency syndrome	0.000505	0.0105	CbGpPWpGaD
Alprostadil—PTGER1—Class A/1 (Rhodopsin-like receptors)—ACKR1—acquired immunodeficiency syndrome	0.000505	0.0105	CbGpPWpGaD
Alprostadil—PTGER2—GPCRs, Class A Rhodopsin-like—CCR2—acquired immunodeficiency syndrome	0.000488	0.0102	CbGpPWpGaD
Alprostadil—PTGER2—Signaling by GPCR—CCL3L1—acquired immunodeficiency syndrome	0.000482	0.0101	CbGpPWpGaD
Alprostadil—PTGER2—Class A/1 (Rhodopsin-like receptors)—CCL3—acquired immunodeficiency syndrome	0.000462	0.00964	CbGpPWpGaD
Alprostadil—PTGER2—GPCRs, Class A Rhodopsin-like—CXCR4—acquired immunodeficiency syndrome	0.000459	0.00957	CbGpPWpGaD
Alprostadil—PTGER1—Class A/1 (Rhodopsin-like receptors)—CCL4—acquired immunodeficiency syndrome	0.000457	0.00954	CbGpPWpGaD
Alprostadil—PTGIR—Class A/1 (Rhodopsin-like receptors)—CCL4—acquired immunodeficiency syndrome	0.000457	0.00954	CbGpPWpGaD
Alprostadil—PTGER2—Class A/1 (Rhodopsin-like receptors)—CCR2—acquired immunodeficiency syndrome	0.000418	0.00872	CbGpPWpGaD
Alprostadil—PTGER2—Class A/1 (Rhodopsin-like receptors)—CXCR4—acquired immunodeficiency syndrome	0.000393	0.0082	CbGpPWpGaD
Alprostadil—PTGER2—Class A/1 (Rhodopsin-like receptors)—CXCL12—acquired immunodeficiency syndrome	0.000393	0.0082	CbGpPWpGaD
Alprostadil—PTGIR—GPCR ligand binding—ACKR1—acquired immunodeficiency syndrome	0.000385	0.00803	CbGpPWpGaD
Alprostadil—PTGER1—GPCR ligand binding—ACKR1—acquired immunodeficiency syndrome	0.000385	0.00803	CbGpPWpGaD
Alprostadil—PTGER2—GPCR ligand binding—CCL3—acquired immunodeficiency syndrome	0.000352	0.00734	CbGpPWpGaD
Alprostadil—PTGIR—GPCR ligand binding—CCL4—acquired immunodeficiency syndrome	0.000348	0.00726	CbGpPWpGaD
Alprostadil—PTGER1—GPCR ligand binding—CCL4—acquired immunodeficiency syndrome	0.000348	0.00726	CbGpPWpGaD
Alprostadil—PTGER1—GPCRs, Class A Rhodopsin-like—CCR2—acquired immunodeficiency syndrome	0.000329	0.00688	CbGpPWpGaD
Alprostadil—PTGIR—GPCRs, Class A Rhodopsin-like—CCR2—acquired immunodeficiency syndrome	0.000329	0.00688	CbGpPWpGaD
Alprostadil—PTGIR—Signaling by GPCR—CCL3L1—acquired immunodeficiency syndrome	0.000326	0.0068	CbGpPWpGaD
Alprostadil—PTGER1—Signaling by GPCR—CCL3L1—acquired immunodeficiency syndrome	0.000326	0.0068	CbGpPWpGaD
Alprostadil—PTGER2—GPCR ligand binding—CCR2—acquired immunodeficiency syndrome	0.000318	0.00664	CbGpPWpGaD
Alprostadil—PTGER2—GPCRs, Class A Rhodopsin-like—CCR5—acquired immunodeficiency syndrome	0.000314	0.00656	CbGpPWpGaD
Alprostadil—PTGIR—Class A/1 (Rhodopsin-like receptors)—CCL3—acquired immunodeficiency syndrome	0.000312	0.00651	CbGpPWpGaD
Alprostadil—PTGER1—Class A/1 (Rhodopsin-like receptors)—CCL3—acquired immunodeficiency syndrome	0.000312	0.00651	CbGpPWpGaD
Alprostadil—PTGIR—GPCRs, Class A Rhodopsin-like—CXCR4—acquired immunodeficiency syndrome	0.00031	0.00647	CbGpPWpGaD
Alprostadil—PTGER1—GPCRs, Class A Rhodopsin-like—CXCR4—acquired immunodeficiency syndrome	0.00031	0.00647	CbGpPWpGaD
Alprostadil—PTGER2—GPCR ligand binding—CXCR4—acquired immunodeficiency syndrome	0.000299	0.00624	CbGpPWpGaD
Alprostadil—PTGER2—GPCR ligand binding—CXCL12—acquired immunodeficiency syndrome	0.000299	0.00624	CbGpPWpGaD
Alprostadil—PTGER2—Class A/1 (Rhodopsin-like receptors)—CCL5—acquired immunodeficiency syndrome	0.000299	0.00624	CbGpPWpGaD
Alprostadil—PTGER2—Signaling by GPCR—ACKR1—acquired immunodeficiency syndrome	0.000292	0.0061	CbGpPWpGaD
Alprostadil—PTGER2—Signaling Pathways—CCL3L1—acquired immunodeficiency syndrome	0.000285	0.00595	CbGpPWpGaD
Alprostadil—PTGIR—Class A/1 (Rhodopsin-like receptors)—CCR2—acquired immunodeficiency syndrome	0.000282	0.00589	CbGpPWpGaD
Alprostadil—PTGER1—Class A/1 (Rhodopsin-like receptors)—CCR2—acquired immunodeficiency syndrome	0.000282	0.00589	CbGpPWpGaD
Alprostadil—Rhinitis—Lamivudine—acquired immunodeficiency syndrome	0.000277	0.00108	CcSEcCtD
Alprostadil—Loss of consciousness—Indinavir—acquired immunodeficiency syndrome	0.000276	0.00107	CcSEcCtD
Alprostadil—Nervousness—Delavirdine—acquired immunodeficiency syndrome	0.000275	0.00107	CcSEcCtD
Alprostadil—Oedema—Zidovudine—acquired immunodeficiency syndrome	0.000275	0.00107	CcSEcCtD
Alprostadil—Hypoaesthesia—Lamivudine—acquired immunodeficiency syndrome	0.000275	0.00107	CcSEcCtD
Alprostadil—Pharyngitis—Lamivudine—acquired immunodeficiency syndrome	0.000275	0.00107	CcSEcCtD
Alprostadil—Back pain—Delavirdine—acquired immunodeficiency syndrome	0.000274	0.00107	CcSEcCtD
Alprostadil—Anaemia—Efavirenz—acquired immunodeficiency syndrome	0.000274	0.00106	CcSEcCtD
Alprostadil—Diarrhoea—Amprenavir—acquired immunodeficiency syndrome	0.000274	0.00106	CcSEcCtD
Alprostadil—Cough—Indinavir—acquired immunodeficiency syndrome	0.000274	0.00106	CcSEcCtD
Alprostadil—Muscle spasms—Delavirdine—acquired immunodeficiency syndrome	0.000273	0.00106	CcSEcCtD
Alprostadil—Pain—Nelfinavir—acquired immunodeficiency syndrome	0.000272	0.00106	CcSEcCtD
Alprostadil—Pain—Stavudine—acquired immunodeficiency syndrome	0.000271	0.00105	CcSEcCtD
Alprostadil—Shock—Zidovudine—acquired immunodeficiency syndrome	0.000271	0.00105	CcSEcCtD
Alprostadil—Feeling abnormal—Nevirapine—acquired immunodeficiency syndrome	0.00027	0.00105	CcSEcCtD
Alprostadil—Thrombocytopenia—Zidovudine—acquired immunodeficiency syndrome	0.00027	0.00105	CcSEcCtD
Alprostadil—PTGER2—Class A/1 (Rhodopsin-like receptors)—CCR5—acquired immunodeficiency syndrome	0.000269	0.00562	CbGpPWpGaD
Alprostadil—Skin disorder—Zidovudine—acquired immunodeficiency syndrome	0.000267	0.00104	CcSEcCtD
Alprostadil—Pain—Abacavir—acquired immunodeficiency syndrome	0.000267	0.00104	CcSEcCtD
Alprostadil—Hyperhidrosis—Zidovudine—acquired immunodeficiency syndrome	0.000266	0.00103	CcSEcCtD
Alprostadil—Syncope—Efavirenz—acquired immunodeficiency syndrome	0.000266	0.00103	CcSEcCtD
Alprostadil—PTGER1—Class A/1 (Rhodopsin-like receptors)—CXCR4—acquired immunodeficiency syndrome	0.000265	0.00554	CbGpPWpGaD
Alprostadil—PTGIR—Class A/1 (Rhodopsin-like receptors)—CXCR4—acquired immunodeficiency syndrome	0.000265	0.00554	CbGpPWpGaD
Alprostadil—PTGER1—Class A/1 (Rhodopsin-like receptors)—CXCL12—acquired immunodeficiency syndrome	0.000265	0.00554	CbGpPWpGaD
Alprostadil—PTGIR—Class A/1 (Rhodopsin-like receptors)—CXCL12—acquired immunodeficiency syndrome	0.000265	0.00554	CbGpPWpGaD
Alprostadil—PTGER2—Signaling by GPCR—CCL4—acquired immunodeficiency syndrome	0.000264	0.00552	CbGpPWpGaD
Alprostadil—Discomfort—Indinavir—acquired immunodeficiency syndrome	0.000264	0.00102	CcSEcCtD
Alprostadil—Anaemia—Delavirdine—acquired immunodeficiency syndrome	0.000262	0.00102	CcSEcCtD
Alprostadil—Feeling abnormal—Nelfinavir—acquired immunodeficiency syndrome	0.000262	0.00102	CcSEcCtD
Alprostadil—Asthenia—Didanosine—acquired immunodeficiency syndrome	0.000262	0.00102	CcSEcCtD
Alprostadil—Dry mouth—Indinavir—acquired immunodeficiency syndrome	0.000261	0.00101	CcSEcCtD
Alprostadil—Loss of consciousness—Efavirenz—acquired immunodeficiency syndrome	0.00026	0.00101	CcSEcCtD
Alprostadil—Abdominal pain—Nevirapine—acquired immunodeficiency syndrome	0.000259	0.00101	CcSEcCtD
Alprostadil—Body temperature increased—Nevirapine—acquired immunodeficiency syndrome	0.000259	0.00101	CcSEcCtD
Alprostadil—Cough—Efavirenz—acquired immunodeficiency syndrome	0.000259	0.001	CcSEcCtD
Alprostadil—Pruritus—Didanosine—acquired immunodeficiency syndrome	0.000258	0.001	CcSEcCtD
Alprostadil—Feeling abnormal—Abacavir—acquired immunodeficiency syndrome	0.000257	0.000999	CcSEcCtD
Alprostadil—Convulsion—Efavirenz—acquired immunodeficiency syndrome	0.000257	0.000997	CcSEcCtD
Alprostadil—Oedema—Indinavir—acquired immunodeficiency syndrome	0.000256	0.000994	CcSEcCtD
Alprostadil—Hypertension—Efavirenz—acquired immunodeficiency syndrome	0.000256	0.000994	CcSEcCtD
Alprostadil—Nervousness—Ritonavir—acquired immunodeficiency syndrome	0.000255	0.000989	CcSEcCtD
Alprostadil—Syncope—Delavirdine—acquired immunodeficiency syndrome	0.000254	0.000988	CcSEcCtD
Alprostadil—Back pain—Ritonavir—acquired immunodeficiency syndrome	0.000254	0.000985	CcSEcCtD
Alprostadil—Erythema—Saquinavir—acquired immunodeficiency syndrome	0.000252	0.00098	CcSEcCtD
Alprostadil—Rash—Amprenavir—acquired immunodeficiency syndrome	0.000252	0.00098	CcSEcCtD
Alprostadil—Muscle spasms—Ritonavir—acquired immunodeficiency syndrome	0.000252	0.000979	CcSEcCtD
Alprostadil—Dermatitis—Amprenavir—acquired immunodeficiency syndrome	0.000252	0.000979	CcSEcCtD
Alprostadil—Shock—Indinavir—acquired immunodeficiency syndrome	0.000252	0.000978	CcSEcCtD
Alprostadil—Body temperature increased—Nelfinavir—acquired immunodeficiency syndrome	0.000251	0.000975	CcSEcCtD
Alprostadil—Abdominal pain—Nelfinavir—acquired immunodeficiency syndrome	0.000251	0.000975	CcSEcCtD
Alprostadil—Headache—Amprenavir—acquired immunodeficiency syndrome	0.000251	0.000974	CcSEcCtD
Alprostadil—Thrombocytopenia—Indinavir—acquired immunodeficiency syndrome	0.000251	0.000974	CcSEcCtD
Alprostadil—Body temperature increased—Stavudine—acquired immunodeficiency syndrome	0.00025	0.000972	CcSEcCtD
Alprostadil—Abdominal pain—Stavudine—acquired immunodeficiency syndrome	0.00025	0.000972	CcSEcCtD
Alprostadil—Diarrhoea—Didanosine—acquired immunodeficiency syndrome	0.00025	0.000969	CcSEcCtD
Alprostadil—Discomfort—Efavirenz—acquired immunodeficiency syndrome	0.000249	0.000968	CcSEcCtD
Alprostadil—Loss of consciousness—Delavirdine—acquired immunodeficiency syndrome	0.000249	0.000968	CcSEcCtD
Alprostadil—Skin disorder—Indinavir—acquired immunodeficiency syndrome	0.000249	0.000966	CcSEcCtD
Alprostadil—Hyperhidrosis—Indinavir—acquired immunodeficiency syndrome	0.000247	0.000961	CcSEcCtD
Alprostadil—Cough—Delavirdine—acquired immunodeficiency syndrome	0.000247	0.000961	CcSEcCtD
Alprostadil—Dry mouth—Efavirenz—acquired immunodeficiency syndrome	0.000247	0.000958	CcSEcCtD
Alprostadil—Abdominal pain—Abacavir—acquired immunodeficiency syndrome	0.000247	0.000958	CcSEcCtD
Alprostadil—Body temperature increased—Abacavir—acquired immunodeficiency syndrome	0.000247	0.000958	CcSEcCtD
Alprostadil—SLCO2A1—SLC-mediated transmembrane transport—ALB—acquired immunodeficiency syndrome	0.000246	0.00514	CbGpPWpGaD
Alprostadil—Hypertension—Delavirdine—acquired immunodeficiency syndrome	0.000245	0.000951	CcSEcCtD
Alprostadil—Back pain—Saquinavir—acquired immunodeficiency syndrome	0.000244	0.000948	CcSEcCtD
Alprostadil—Muscle spasms—Saquinavir—acquired immunodeficiency syndrome	0.000243	0.000942	CcSEcCtD
Alprostadil—Anaemia—Ritonavir—acquired immunodeficiency syndrome	0.000242	0.000941	CcSEcCtD
Alprostadil—Dyspepsia—Zidovudine—acquired immunodeficiency syndrome	0.000242	0.000941	CcSEcCtD
Alprostadil—Erythema—Lamivudine—acquired immunodeficiency syndrome	0.000241	0.000935	CcSEcCtD
Alprostadil—Discomfort—Delavirdine—acquired immunodeficiency syndrome	0.000239	0.000926	CcSEcCtD
Alprostadil—Shock—Efavirenz—acquired immunodeficiency syndrome	0.000238	0.000924	CcSEcCtD
Alprostadil—Nausea—Amprenavir—acquired immunodeficiency syndrome	0.000238	0.000923	CcSEcCtD
Alprostadil—PTGIR—GPCR ligand binding—CCL3—acquired immunodeficiency syndrome	0.000238	0.00496	CbGpPWpGaD
Alprostadil—PTGER1—GPCR ligand binding—CCL3—acquired immunodeficiency syndrome	0.000238	0.00496	CbGpPWpGaD
Alprostadil—Thrombocytopenia—Efavirenz—acquired immunodeficiency syndrome	0.000237	0.00092	CcSEcCtD
Alprostadil—Dry mouth—Delavirdine—acquired immunodeficiency syndrome	0.000236	0.000917	CcSEcCtD
Alprostadil—Tachycardia—Efavirenz—acquired immunodeficiency syndrome	0.000236	0.000917	CcSEcCtD
Alprostadil—Pain—Zidovudine—acquired immunodeficiency syndrome	0.000235	0.000914	CcSEcCtD
Alprostadil—Asthenia—Nevirapine—acquired immunodeficiency syndrome	0.000235	0.000914	CcSEcCtD
Alprostadil—Syncope—Ritonavir—acquired immunodeficiency syndrome	0.000235	0.000913	CcSEcCtD
Alprostadil—Skin disorder—Efavirenz—acquired immunodeficiency syndrome	0.000235	0.000912	CcSEcCtD
Alprostadil—Nervousness—Lamivudine—acquired immunodeficiency syndrome	0.000234	0.000908	CcSEcCtD
Alprostadil—Hyperhidrosis—Efavirenz—acquired immunodeficiency syndrome	0.000234	0.000908	CcSEcCtD
Alprostadil—SLCO3A1—SLC-mediated transmembrane transport—ALB—acquired immunodeficiency syndrome	0.000233	0.00487	CbGpPWpGaD
Alprostadil—Anaemia—Saquinavir—acquired immunodeficiency syndrome	0.000233	0.000906	CcSEcCtD
Alprostadil—Back pain—Lamivudine—acquired immunodeficiency syndrome	0.000233	0.000905	CcSEcCtD
Alprostadil—Pruritus—Nevirapine—acquired immunodeficiency syndrome	0.000232	0.000901	CcSEcCtD
Alprostadil—Muscle spasms—Lamivudine—acquired immunodeficiency syndrome	0.000231	0.000899	CcSEcCtD
Alprostadil—Oedema—Delavirdine—acquired immunodeficiency syndrome	0.000231	0.000899	CcSEcCtD
Alprostadil—Loss of consciousness—Ritonavir—acquired immunodeficiency syndrome	0.00023	0.000895	CcSEcCtD
Alprostadil—ABCC4—Platelet degranulation—ALB—acquired immunodeficiency syndrome	0.00023	0.0048	CbGpPWpGaD
Alprostadil—Rash—Didanosine—acquired immunodeficiency syndrome	0.00023	0.000893	CcSEcCtD
Alprostadil—Infection—Delavirdine—acquired immunodeficiency syndrome	0.00023	0.000893	CcSEcCtD
Alprostadil—Dermatitis—Didanosine—acquired immunodeficiency syndrome	0.00023	0.000893	CcSEcCtD
Alprostadil—Cough—Ritonavir—acquired immunodeficiency syndrome	0.000229	0.000889	CcSEcCtD
Alprostadil—Headache—Didanosine—acquired immunodeficiency syndrome	0.000229	0.000888	CcSEcCtD
Alprostadil—Asthenia—Nelfinavir—acquired immunodeficiency syndrome	0.000228	0.000885	CcSEcCtD
Alprostadil—Shock—Delavirdine—acquired immunodeficiency syndrome	0.000228	0.000884	CcSEcCtD
Alprostadil—PTGER2—GPCR ligand binding—CCL5—acquired immunodeficiency syndrome	0.000228	0.00475	CbGpPWpGaD
Alprostadil—Asthenia—Stavudine—acquired immunodeficiency syndrome	0.000227	0.000883	CcSEcCtD
Alprostadil—Convulsion—Ritonavir—acquired immunodeficiency syndrome	0.000227	0.000882	CcSEcCtD
Alprostadil—Feeling abnormal—Zidovudine—acquired immunodeficiency syndrome	0.000227	0.000881	CcSEcCtD
Alprostadil—Thrombocytopenia—Delavirdine—acquired immunodeficiency syndrome	0.000227	0.00088	CcSEcCtD
Alprostadil—Hypertension—Ritonavir—acquired immunodeficiency syndrome	0.000226	0.000879	CcSEcCtD
Alprostadil—Syncope—Saquinavir—acquired immunodeficiency syndrome	0.000226	0.000879	CcSEcCtD
Alprostadil—Tachycardia—Delavirdine—acquired immunodeficiency syndrome	0.000226	0.000877	CcSEcCtD
Alprostadil—Dyspepsia—Indinavir—acquired immunodeficiency syndrome	0.000225	0.000875	CcSEcCtD
Alprostadil—Skin disorder—Delavirdine—acquired immunodeficiency syndrome	0.000225	0.000873	CcSEcCtD
Alprostadil—Pruritus—Nelfinavir—acquired immunodeficiency syndrome	0.000225	0.000873	CcSEcCtD
Alprostadil—Diarrhoea—Nevirapine—acquired immunodeficiency syndrome	0.000224	0.000872	CcSEcCtD
Alprostadil—Pruritus—Stavudine—acquired immunodeficiency syndrome	0.000224	0.00087	CcSEcCtD
Alprostadil—Asthenia—Abacavir—acquired immunodeficiency syndrome	0.000224	0.000869	CcSEcCtD
Alprostadil—Hyperhidrosis—Delavirdine—acquired immunodeficiency syndrome	0.000224	0.000869	CcSEcCtD
Alprostadil—Anaemia—Lamivudine—acquired immunodeficiency syndrome	0.000223	0.000864	CcSEcCtD
Alprostadil—Loss of consciousness—Saquinavir—acquired immunodeficiency syndrome	0.000222	0.000862	CcSEcCtD
Alprostadil—Pruritus—Abacavir—acquired immunodeficiency syndrome	0.000221	0.000857	CcSEcCtD
Alprostadil—Discomfort—Ritonavir—acquired immunodeficiency syndrome	0.000221	0.000857	CcSEcCtD
Alprostadil—Cough—Saquinavir—acquired immunodeficiency syndrome	0.00022	0.000855	CcSEcCtD
Alprostadil—ABCC4—Response to elevated platelet cytosolic Ca2+—ALB—acquired immunodeficiency syndrome	0.000219	0.00457	CbGpPWpGaD
Alprostadil—Pain—Indinavir—acquired immunodeficiency syndrome	0.000219	0.00085	CcSEcCtD
Alprostadil—Convulsion—Saquinavir—acquired immunodeficiency syndrome	0.000219	0.000849	CcSEcCtD
Alprostadil—Dry mouth—Ritonavir—acquired immunodeficiency syndrome	0.000218	0.000848	CcSEcCtD
Alprostadil—Hypertension—Saquinavir—acquired immunodeficiency syndrome	0.000218	0.000846	CcSEcCtD
Alprostadil—Abdominal pain—Zidovudine—acquired immunodeficiency syndrome	0.000218	0.000845	CcSEcCtD
Alprostadil—Body temperature increased—Zidovudine—acquired immunodeficiency syndrome	0.000218	0.000845	CcSEcCtD
Alprostadil—Diarrhoea—Nelfinavir—acquired immunodeficiency syndrome	0.000217	0.000844	CcSEcCtD
Alprostadil—Diarrhoea—Stavudine—acquired immunodeficiency syndrome	0.000217	0.000842	CcSEcCtD
Alprostadil—Nausea—Didanosine—acquired immunodeficiency syndrome	0.000217	0.000842	CcSEcCtD
Alprostadil—Hypotension—Delavirdine—acquired immunodeficiency syndrome	0.000216	0.00084	CcSEcCtD
Alprostadil—Syncope—Lamivudine—acquired immunodeficiency syndrome	0.000216	0.000839	CcSEcCtD
Alprostadil—PTGER1—GPCR ligand binding—CCR2—acquired immunodeficiency syndrome	0.000215	0.00449	CbGpPWpGaD
Alprostadil—PTGIR—GPCR ligand binding—CCR2—acquired immunodeficiency syndrome	0.000215	0.00449	CbGpPWpGaD
Alprostadil—Oedema—Ritonavir—acquired immunodeficiency syndrome	0.000214	0.000831	CcSEcCtD
Alprostadil—Diarrhoea—Abacavir—acquired immunodeficiency syndrome	0.000213	0.000829	CcSEcCtD
Alprostadil—Dyspepsia—Efavirenz—acquired immunodeficiency syndrome	0.000213	0.000827	CcSEcCtD
Alprostadil—PTGIR—GPCRs, Class A Rhodopsin-like—CCR5—acquired immunodeficiency syndrome	0.000212	0.00443	CbGpPWpGaD
Alprostadil—PTGER1—GPCRs, Class A Rhodopsin-like—CCR5—acquired immunodeficiency syndrome	0.000212	0.00443	CbGpPWpGaD
Alprostadil—Discomfort—Saquinavir—acquired immunodeficiency syndrome	0.000212	0.000825	CcSEcCtD
Alprostadil—Loss of consciousness—Lamivudine—acquired immunodeficiency syndrome	0.000212	0.000822	CcSEcCtD
Alprostadil—Feeling abnormal—Indinavir—acquired immunodeficiency syndrome	0.000211	0.000819	CcSEcCtD
Alprostadil—Shock—Ritonavir—acquired immunodeficiency syndrome	0.000211	0.000818	CcSEcCtD
Alprostadil—Dry mouth—Saquinavir—acquired immunodeficiency syndrome	0.00021	0.000816	CcSEcCtD
Alprostadil—Cough—Lamivudine—acquired immunodeficiency syndrome	0.00021	0.000816	CcSEcCtD
Alprostadil—Dizziness—Nelfinavir—acquired immunodeficiency syndrome	0.00021	0.000816	CcSEcCtD
Alprostadil—Thrombocytopenia—Ritonavir—acquired immunodeficiency syndrome	0.00021	0.000814	CcSEcCtD
Alprostadil—Dizziness—Stavudine—acquired immunodeficiency syndrome	0.000209	0.000813	CcSEcCtD
Alprostadil—Tachycardia—Ritonavir—acquired immunodeficiency syndrome	0.000209	0.000811	CcSEcCtD
Alprostadil—Convulsion—Lamivudine—acquired immunodeficiency syndrome	0.000209	0.00081	CcSEcCtD
Alprostadil—Skin disorder—Ritonavir—acquired immunodeficiency syndrome	0.000208	0.000807	CcSEcCtD
Alprostadil—Hyperhidrosis—Ritonavir—acquired immunodeficiency syndrome	0.000207	0.000804	CcSEcCtD
Alprostadil—Pain—Efavirenz—acquired immunodeficiency syndrome	0.000207	0.000803	CcSEcCtD
Alprostadil—Rash—Nevirapine—acquired immunodeficiency syndrome	0.000207	0.000803	CcSEcCtD
Alprostadil—Dermatitis—Nevirapine—acquired immunodeficiency syndrome	0.000207	0.000803	CcSEcCtD
Alprostadil—Dizziness—Abacavir—acquired immunodeficiency syndrome	0.000206	0.000801	CcSEcCtD
Alprostadil—Oedema—Saquinavir—acquired immunodeficiency syndrome	0.000206	0.0008	CcSEcCtD
Alprostadil—Headache—Nevirapine—acquired immunodeficiency syndrome	0.000205	0.000798	CcSEcCtD
Alprostadil—PTGER2—GPCR ligand binding—CCR5—acquired immunodeficiency syndrome	0.000205	0.00428	CbGpPWpGaD
Alprostadil—Infection—Saquinavir—acquired immunodeficiency syndrome	0.000205	0.000795	CcSEcCtD
Alprostadil—Dyspepsia—Delavirdine—acquired immunodeficiency syndrome	0.000204	0.000791	CcSEcCtD
Alprostadil—Shock—Saquinavir—acquired immunodeficiency syndrome	0.000203	0.000787	CcSEcCtD
Alprostadil—Discomfort—Lamivudine—acquired immunodeficiency syndrome	0.000203	0.000787	CcSEcCtD
Alprostadil—Body temperature increased—Indinavir—acquired immunodeficiency syndrome	0.000202	0.000786	CcSEcCtD
Alprostadil—Abdominal pain—Indinavir—acquired immunodeficiency syndrome	0.000202	0.000786	CcSEcCtD
Alprostadil—PTGIR—GPCR ligand binding—CXCR4—acquired immunodeficiency syndrome	0.000202	0.00422	CbGpPWpGaD
Alprostadil—PTGER1—GPCR ligand binding—CXCR4—acquired immunodeficiency syndrome	0.000202	0.00422	CbGpPWpGaD
Alprostadil—PTGER1—GPCR ligand binding—CXCL12—acquired immunodeficiency syndrome	0.000202	0.00422	CbGpPWpGaD
Alprostadil—PTGIR—GPCR ligand binding—CXCL12—acquired immunodeficiency syndrome	0.000202	0.00422	CbGpPWpGaD
Alprostadil—PTGER1—Class A/1 (Rhodopsin-like receptors)—CCL5—acquired immunodeficiency syndrome	0.000202	0.00421	CbGpPWpGaD
Alprostadil—PTGIR—Class A/1 (Rhodopsin-like receptors)—CCL5—acquired immunodeficiency syndrome	0.000202	0.00421	CbGpPWpGaD
Alprostadil—Thrombocytopenia—Saquinavir—acquired immunodeficiency syndrome	0.000202	0.000783	CcSEcCtD
Alprostadil—Dry mouth—Lamivudine—acquired immunodeficiency syndrome	0.0002	0.000779	CcSEcCtD
Alprostadil—Rash—Nelfinavir—acquired immunodeficiency syndrome	0.0002	0.000778	CcSEcCtD
Alprostadil—Dermatitis—Nelfinavir—acquired immunodeficiency syndrome	0.0002	0.000777	CcSEcCtD
Alprostadil—Skin disorder—Saquinavir—acquired immunodeficiency syndrome	0.0002	0.000777	CcSEcCtD
Alprostadil—Hypotension—Ritonavir—acquired immunodeficiency syndrome	0.0002	0.000777	CcSEcCtD
Alprostadil—Rash—Stavudine—acquired immunodeficiency syndrome	0.0002	0.000776	CcSEcCtD
Alprostadil—Dermatitis—Stavudine—acquired immunodeficiency syndrome	0.0002	0.000775	CcSEcCtD
Alprostadil—Feeling abnormal—Efavirenz—acquired immunodeficiency syndrome	0.000199	0.000774	CcSEcCtD
Alprostadil—Hyperhidrosis—Saquinavir—acquired immunodeficiency syndrome	0.000199	0.000773	CcSEcCtD
Alprostadil—Headache—Nelfinavir—acquired immunodeficiency syndrome	0.000199	0.000773	CcSEcCtD
Alprostadil—Headache—Stavudine—acquired immunodeficiency syndrome	0.000198	0.000771	CcSEcCtD
Alprostadil—Pain—Delavirdine—acquired immunodeficiency syndrome	0.000198	0.000769	CcSEcCtD
Alprostadil—Asthenia—Zidovudine—acquired immunodeficiency syndrome	0.000198	0.000767	CcSEcCtD
Alprostadil—PTGER1—Signaling by GPCR—ACKR1—acquired immunodeficiency syndrome	0.000197	0.00412	CbGpPWpGaD
Alprostadil—PTGIR—Signaling by GPCR—ACKR1—acquired immunodeficiency syndrome	0.000197	0.00412	CbGpPWpGaD
Alprostadil—Rash—Abacavir—acquired immunodeficiency syndrome	0.000197	0.000764	CcSEcCtD
Alprostadil—Dermatitis—Abacavir—acquired immunodeficiency syndrome	0.000197	0.000763	CcSEcCtD
Alprostadil—Oedema—Lamivudine—acquired immunodeficiency syndrome	0.000197	0.000763	CcSEcCtD
Alprostadil—Headache—Abacavir—acquired immunodeficiency syndrome	0.000195	0.000759	CcSEcCtD
Alprostadil—Infection—Lamivudine—acquired immunodeficiency syndrome	0.000195	0.000758	CcSEcCtD
Alprostadil—Nausea—Nevirapine—acquired immunodeficiency syndrome	0.000195	0.000757	CcSEcCtD
Alprostadil—Pruritus—Zidovudine—acquired immunodeficiency syndrome	0.000195	0.000756	CcSEcCtD
Alprostadil—Shock—Lamivudine—acquired immunodeficiency syndrome	0.000193	0.000751	CcSEcCtD
Alprostadil—PTGER1—Signaling Pathways—CCL3L1—acquired immunodeficiency syndrome	0.000193	0.00402	CbGpPWpGaD
Alprostadil—PTGIR—Signaling Pathways—CCL3L1—acquired immunodeficiency syndrome	0.000193	0.00402	CbGpPWpGaD
Alprostadil—Hypotension—Saquinavir—acquired immunodeficiency syndrome	0.000192	0.000748	CcSEcCtD
Alprostadil—Thrombocytopenia—Lamivudine—acquired immunodeficiency syndrome	0.000192	0.000747	CcSEcCtD
Alprostadil—Abdominal pain—Efavirenz—acquired immunodeficiency syndrome	0.000191	0.000743	CcSEcCtD
Alprostadil—Body temperature increased—Efavirenz—acquired immunodeficiency syndrome	0.000191	0.000743	CcSEcCtD
Alprostadil—Skin disorder—Lamivudine—acquired immunodeficiency syndrome	0.000191	0.000741	CcSEcCtD
Alprostadil—Feeling abnormal—Delavirdine—acquired immunodeficiency syndrome	0.000191	0.000741	CcSEcCtD
Alprostadil—Hyperhidrosis—Lamivudine—acquired immunodeficiency syndrome	0.00019	0.000738	CcSEcCtD
Alprostadil—Nausea—Nelfinavir—acquired immunodeficiency syndrome	0.000189	0.000733	CcSEcCtD
Alprostadil—Dyspepsia—Ritonavir—acquired immunodeficiency syndrome	0.000188	0.000732	CcSEcCtD
Alprostadil—Diarrhoea—Zidovudine—acquired immunodeficiency syndrome	0.000188	0.000732	CcSEcCtD
Alprostadil—Nausea—Stavudine—acquired immunodeficiency syndrome	0.000188	0.000731	CcSEcCtD
Alprostadil—Nausea—Abacavir—acquired immunodeficiency syndrome	0.000185	0.00072	CcSEcCtD
Alprostadil—Asthenia—Indinavir—acquired immunodeficiency syndrome	0.000184	0.000713	CcSEcCtD
Alprostadil—Hypotension—Lamivudine—acquired immunodeficiency syndrome	0.000184	0.000713	CcSEcCtD
Alprostadil—Pain—Ritonavir—acquired immunodeficiency syndrome	0.000183	0.000711	CcSEcCtD
Alprostadil—Body temperature increased—Delavirdine—acquired immunodeficiency syndrome	0.000183	0.000711	CcSEcCtD
Alprostadil—Abdominal pain—Delavirdine—acquired immunodeficiency syndrome	0.000183	0.000711	CcSEcCtD
Alprostadil—Dizziness—Zidovudine—acquired immunodeficiency syndrome	0.000182	0.000707	CcSEcCtD
Alprostadil—PTGIR—Class A/1 (Rhodopsin-like receptors)—CCR5—acquired immunodeficiency syndrome	0.000182	0.0038	CbGpPWpGaD
Alprostadil—PTGER1—Class A/1 (Rhodopsin-like receptors)—CCR5—acquired immunodeficiency syndrome	0.000182	0.0038	CbGpPWpGaD
Alprostadil—Dyspepsia—Saquinavir—acquired immunodeficiency syndrome	0.000181	0.000704	CcSEcCtD
Alprostadil—Pruritus—Indinavir—acquired immunodeficiency syndrome	0.000181	0.000703	CcSEcCtD
Alprostadil—PTGER2—Signaling by GPCR—CCL3—acquired immunodeficiency syndrome	0.000181	0.00377	CbGpPWpGaD
Alprostadil—PTGER2—GPCR downstream signaling—CCR2—acquired immunodeficiency syndrome	0.00018	0.00375	CbGpPWpGaD
Alprostadil—PTGER1—Signaling by GPCR—CCL4—acquired immunodeficiency syndrome	0.000179	0.00373	CbGpPWpGaD
Alprostadil—PTGIR—Signaling by GPCR—CCL4—acquired immunodeficiency syndrome	0.000179	0.00373	CbGpPWpGaD
Alprostadil—ABCC5—Metabolism—TAT—acquired immunodeficiency syndrome	0.000176	0.00368	CbGpPWpGaD
Alprostadil—Feeling abnormal—Ritonavir—acquired immunodeficiency syndrome	0.000176	0.000685	CcSEcCtD
Alprostadil—Pain—Saquinavir—acquired immunodeficiency syndrome	0.000176	0.000684	CcSEcCtD
Alprostadil—Diarrhoea—Indinavir—acquired immunodeficiency syndrome	0.000175	0.00068	CcSEcCtD
Alprostadil—Rash—Zidovudine—acquired immunodeficiency syndrome	0.000174	0.000674	CcSEcCtD
Alprostadil—Asthenia—Efavirenz—acquired immunodeficiency syndrome	0.000174	0.000674	CcSEcCtD
Alprostadil—Dermatitis—Zidovudine—acquired immunodeficiency syndrome	0.000173	0.000673	CcSEcCtD
Alprostadil—PTGIR—Hemostasis—IFNA1—acquired immunodeficiency syndrome	0.000173	0.00361	CbGpPWpGaD
Alprostadil—Dyspepsia—Lamivudine—acquired immunodeficiency syndrome	0.000173	0.000672	CcSEcCtD
Alprostadil—PTGER2—Signaling Pathways—CCNT1—acquired immunodeficiency syndrome	0.000173	0.0036	CbGpPWpGaD
Alprostadil—PTGER2—Signaling Pathways—ACKR1—acquired immunodeficiency syndrome	0.000173	0.0036	CbGpPWpGaD
Alprostadil—Headache—Zidovudine—acquired immunodeficiency syndrome	0.000172	0.00067	CcSEcCtD
Alprostadil—Pruritus—Efavirenz—acquired immunodeficiency syndrome	0.000171	0.000665	CcSEcCtD
Alprostadil—Feeling abnormal—Saquinavir—acquired immunodeficiency syndrome	0.00017	0.000659	CcSEcCtD
Alprostadil—Dizziness—Indinavir—acquired immunodeficiency syndrome	0.000169	0.000658	CcSEcCtD
Alprostadil—Abdominal pain—Ritonavir—acquired immunodeficiency syndrome	0.000169	0.000657	CcSEcCtD
Alprostadil—Body temperature increased—Ritonavir—acquired immunodeficiency syndrome	0.000169	0.000657	CcSEcCtD
Alprostadil—PTGER2—GPCR downstream signaling—CXCR4—acquired immunodeficiency syndrome	0.000169	0.00353	CbGpPWpGaD
Alprostadil—PTGER2—GPCR downstream signaling—CXCL12—acquired immunodeficiency syndrome	0.000169	0.00353	CbGpPWpGaD
Alprostadil—ABCC5—Disease—APOBEC3G—acquired immunodeficiency syndrome	0.000168	0.00352	CbGpPWpGaD
Alprostadil—Pain—Lamivudine—acquired immunodeficiency syndrome	0.000168	0.000653	CcSEcCtD
Alprostadil—Asthenia—Delavirdine—acquired immunodeficiency syndrome	0.000166	0.000645	CcSEcCtD
Alprostadil—Diarrhoea—Efavirenz—acquired immunodeficiency syndrome	0.000165	0.000643	CcSEcCtD
Alprostadil—Pruritus—Delavirdine—acquired immunodeficiency syndrome	0.000164	0.000636	CcSEcCtD
Alprostadil—Nausea—Zidovudine—acquired immunodeficiency syndrome	0.000164	0.000635	CcSEcCtD
Alprostadil—PTGER2—Signaling by GPCR—CCR2—acquired immunodeficiency syndrome	0.000163	0.00341	CbGpPWpGaD
Alprostadil—Body temperature increased—Saquinavir—acquired immunodeficiency syndrome	0.000163	0.000632	CcSEcCtD
Alprostadil—Abdominal pain—Saquinavir—acquired immunodeficiency syndrome	0.000163	0.000632	CcSEcCtD
Alprostadil—Feeling abnormal—Lamivudine—acquired immunodeficiency syndrome	0.000162	0.000629	CcSEcCtD
Alprostadil—Rash—Indinavir—acquired immunodeficiency syndrome	0.000161	0.000627	CcSEcCtD
Alprostadil—Dermatitis—Indinavir—acquired immunodeficiency syndrome	0.000161	0.000626	CcSEcCtD
Alprostadil—Headache—Indinavir—acquired immunodeficiency syndrome	0.00016	0.000623	CcSEcCtD
Alprostadil—Dizziness—Efavirenz—acquired immunodeficiency syndrome	0.00016	0.000621	CcSEcCtD
Alprostadil—Diarrhoea—Delavirdine—acquired immunodeficiency syndrome	0.000158	0.000615	CcSEcCtD
Alprostadil—ABCC4—Platelet activation, signaling and aggregation—CSF2—acquired immunodeficiency syndrome	0.000157	0.00327	CbGpPWpGaD
Alprostadil—PTGER2—Signaling Pathways—CCL4—acquired immunodeficiency syndrome	0.000156	0.00326	CbGpPWpGaD
Alprostadil—Abdominal pain—Lamivudine—acquired immunodeficiency syndrome	0.000155	0.000603	CcSEcCtD
Alprostadil—Body temperature increased—Lamivudine—acquired immunodeficiency syndrome	0.000155	0.000603	CcSEcCtD
Alprostadil—PTGIR—GPCR ligand binding—CCL5—acquired immunodeficiency syndrome	0.000154	0.00321	CbGpPWpGaD
Alprostadil—PTGER1—GPCR ligand binding—CCL5—acquired immunodeficiency syndrome	0.000154	0.00321	CbGpPWpGaD
Alprostadil—Asthenia—Ritonavir—acquired immunodeficiency syndrome	0.000154	0.000596	CcSEcCtD
Alprostadil—PTGER2—Signaling by GPCR—CXCR4—acquired immunodeficiency syndrome	0.000154	0.0032	CbGpPWpGaD
Alprostadil—PTGER2—Signaling by GPCR—CXCL12—acquired immunodeficiency syndrome	0.000154	0.0032	CbGpPWpGaD
Alprostadil—Dizziness—Delavirdine—acquired immunodeficiency syndrome	0.000153	0.000594	CcSEcCtD
Alprostadil—Rash—Efavirenz—acquired immunodeficiency syndrome	0.000153	0.000592	CcSEcCtD
Alprostadil—Dermatitis—Efavirenz—acquired immunodeficiency syndrome	0.000152	0.000592	CcSEcCtD
Alprostadil—Nausea—Indinavir—acquired immunodeficiency syndrome	0.000152	0.000591	CcSEcCtD
Alprostadil—Headache—Efavirenz—acquired immunodeficiency syndrome	0.000152	0.000589	CcSEcCtD
Alprostadil—Pruritus—Ritonavir—acquired immunodeficiency syndrome	0.000151	0.000588	CcSEcCtD
Alprostadil—ABCC5—Metabolism—AGPS—acquired immunodeficiency syndrome	0.00015	0.00313	CbGpPWpGaD
Alprostadil—Asthenia—Saquinavir—acquired immunodeficiency syndrome	0.000148	0.000574	CcSEcCtD
Alprostadil—Diarrhoea—Ritonavir—acquired immunodeficiency syndrome	0.000146	0.000569	CcSEcCtD
Alprostadil—Rash—Delavirdine—acquired immunodeficiency syndrome	0.000146	0.000567	CcSEcCtD
Alprostadil—Dermatitis—Delavirdine—acquired immunodeficiency syndrome	0.000146	0.000566	CcSEcCtD
Alprostadil—Pruritus—Saquinavir—acquired immunodeficiency syndrome	0.000146	0.000566	CcSEcCtD
Alprostadil—Headache—Delavirdine—acquired immunodeficiency syndrome	0.000145	0.000563	CcSEcCtD
Alprostadil—Nausea—Efavirenz—acquired immunodeficiency syndrome	0.000144	0.000558	CcSEcCtD
Alprostadil—ABCC5—Disease—CCNT1—acquired immunodeficiency syndrome	0.000143	0.00299	CbGpPWpGaD
Alprostadil—Dizziness—Ritonavir—acquired immunodeficiency syndrome	0.000142	0.00055	CcSEcCtD
Alprostadil—Asthenia—Lamivudine—acquired immunodeficiency syndrome	0.000141	0.000548	CcSEcCtD
Alprostadil—Diarrhoea—Saquinavir—acquired immunodeficiency syndrome	0.000141	0.000547	CcSEcCtD
Alprostadil—Pruritus—Lamivudine—acquired immunodeficiency syndrome	0.000139	0.00054	CcSEcCtD
Alprostadil—PTGIR—GPCR ligand binding—CCR5—acquired immunodeficiency syndrome	0.000139	0.00289	CbGpPWpGaD
Alprostadil—PTGER1—GPCR ligand binding—CCR5—acquired immunodeficiency syndrome	0.000139	0.00289	CbGpPWpGaD
Alprostadil—Nausea—Delavirdine—acquired immunodeficiency syndrome	0.000137	0.000534	CcSEcCtD
Alprostadil—Dizziness—Saquinavir—acquired immunodeficiency syndrome	0.000136	0.000529	CcSEcCtD
Alprostadil—PTGIR—Hemostasis—CSF2—acquired immunodeficiency syndrome	0.000135	0.00283	CbGpPWpGaD
Alprostadil—SLCO2B1—SLC-mediated transmembrane transport—ALB—acquired immunodeficiency syndrome	0.000135	0.00282	CbGpPWpGaD
Alprostadil—Rash—Ritonavir—acquired immunodeficiency syndrome	0.000135	0.000524	CcSEcCtD
Alprostadil—Dermatitis—Ritonavir—acquired immunodeficiency syndrome	0.000135	0.000524	CcSEcCtD
Alprostadil—Diarrhoea—Lamivudine—acquired immunodeficiency syndrome	0.000134	0.000522	CcSEcCtD
Alprostadil—Headache—Ritonavir—acquired immunodeficiency syndrome	0.000134	0.000521	CcSEcCtD
Alprostadil—Dizziness—Lamivudine—acquired immunodeficiency syndrome	0.00013	0.000505	CcSEcCtD
Alprostadil—Rash—Saquinavir—acquired immunodeficiency syndrome	0.00013	0.000504	CcSEcCtD
Alprostadil—Dermatitis—Saquinavir—acquired immunodeficiency syndrome	0.00013	0.000504	CcSEcCtD
Alprostadil—Headache—Saquinavir—acquired immunodeficiency syndrome	0.000129	0.000501	CcSEcCtD
Alprostadil—PTGER2—GPCR downstream signaling—CCL5—acquired immunodeficiency syndrome	0.000129	0.00268	CbGpPWpGaD
Alprostadil—Nausea—Ritonavir—acquired immunodeficiency syndrome	0.000127	0.000494	CcSEcCtD
Alprostadil—PTGER2—GPCR downstream signaling—CSF2—acquired immunodeficiency syndrome	0.000127	0.00264	CbGpPWpGaD
Alprostadil—SLCO2A1—Transmembrane transport of small molecules—ALB—acquired immunodeficiency syndrome	0.000125	0.00261	CbGpPWpGaD
Alprostadil—Rash—Lamivudine—acquired immunodeficiency syndrome	0.000124	0.000481	CcSEcCtD
Alprostadil—Dermatitis—Lamivudine—acquired immunodeficiency syndrome	0.000124	0.000481	CcSEcCtD
Alprostadil—Headache—Lamivudine—acquired immunodeficiency syndrome	0.000123	0.000478	CcSEcCtD
Alprostadil—Nausea—Saquinavir—acquired immunodeficiency syndrome	0.000122	0.000475	CcSEcCtD
Alprostadil—PTGIR—Signaling by GPCR—CCL3—acquired immunodeficiency syndrome	0.000122	0.00255	CbGpPWpGaD
Alprostadil—PTGER1—Signaling by GPCR—CCL3—acquired immunodeficiency syndrome	0.000122	0.00255	CbGpPWpGaD
Alprostadil—PTGER1—GPCR downstream signaling—CCR2—acquired immunodeficiency syndrome	0.000121	0.00254	CbGpPWpGaD
Alprostadil—PTGIR—GPCR downstream signaling—CCR2—acquired immunodeficiency syndrome	0.000121	0.00254	CbGpPWpGaD
Alprostadil—SLCO3A1—Transmembrane transport of small molecules—ALB—acquired immunodeficiency syndrome	0.000119	0.00247	CbGpPWpGaD
Alprostadil—PTGER2—Signaling by GPCR—CCL5—acquired immunodeficiency syndrome	0.000117	0.00244	CbGpPWpGaD
Alprostadil—Nausea—Lamivudine—acquired immunodeficiency syndrome	0.000117	0.000453	CcSEcCtD
Alprostadil—PTGER1—Signaling Pathways—CCNT1—acquired immunodeficiency syndrome	0.000117	0.00243	CbGpPWpGaD
Alprostadil—PTGIR—Signaling Pathways—CCNT1—acquired immunodeficiency syndrome	0.000117	0.00243	CbGpPWpGaD
Alprostadil—PTGER1—Signaling Pathways—ACKR1—acquired immunodeficiency syndrome	0.000117	0.00243	CbGpPWpGaD
Alprostadil—PTGIR—Signaling Pathways—ACKR1—acquired immunodeficiency syndrome	0.000117	0.00243	CbGpPWpGaD
Alprostadil—PTGER2—GPCR downstream signaling—CCR5—acquired immunodeficiency syndrome	0.000116	0.00242	CbGpPWpGaD
Alprostadil—PTGER2—Signaling by GPCR—CSF2—acquired immunodeficiency syndrome	0.000115	0.0024	CbGpPWpGaD
Alprostadil—PTGER1—GPCR downstream signaling—CXCR4—acquired immunodeficiency syndrome	0.000114	0.00238	CbGpPWpGaD
Alprostadil—PTGIR—GPCR downstream signaling—CXCR4—acquired immunodeficiency syndrome	0.000114	0.00238	CbGpPWpGaD
Alprostadil—PTGIR—GPCR downstream signaling—CXCL12—acquired immunodeficiency syndrome	0.000114	0.00238	CbGpPWpGaD
Alprostadil—PTGER1—GPCR downstream signaling—CXCL12—acquired immunodeficiency syndrome	0.000114	0.00238	CbGpPWpGaD
Alprostadil—PTGIR—Signaling by GPCR—CCR2—acquired immunodeficiency syndrome	0.00011	0.0023	CbGpPWpGaD
Alprostadil—PTGER1—Signaling by GPCR—CCR2—acquired immunodeficiency syndrome	0.00011	0.0023	CbGpPWpGaD
Alprostadil—PTGER2—Signaling Pathways—CCL3—acquired immunodeficiency syndrome	0.000107	0.00223	CbGpPWpGaD
Alprostadil—PTGER1—Signaling Pathways—CCL4—acquired immunodeficiency syndrome	0.000105	0.0022	CbGpPWpGaD
Alprostadil—PTGIR—Signaling Pathways—CCL4—acquired immunodeficiency syndrome	0.000105	0.0022	CbGpPWpGaD
Alprostadil—PTGER2—Signaling by GPCR—CCR5—acquired immunodeficiency syndrome	0.000105	0.0022	CbGpPWpGaD
Alprostadil—PTGER1—Signaling by GPCR—CXCL12—acquired immunodeficiency syndrome	0.000104	0.00216	CbGpPWpGaD
Alprostadil—PTGIR—Signaling by GPCR—CXCR4—acquired immunodeficiency syndrome	0.000104	0.00216	CbGpPWpGaD
Alprostadil—PTGER1—Signaling by GPCR—CXCR4—acquired immunodeficiency syndrome	0.000104	0.00216	CbGpPWpGaD
Alprostadil—PTGIR—Signaling by GPCR—CXCL12—acquired immunodeficiency syndrome	0.000104	0.00216	CbGpPWpGaD
Alprostadil—ABCC4—Hemostasis—IFNA1—acquired immunodeficiency syndrome	0.000103	0.00215	CbGpPWpGaD
Alprostadil—ABCC4—Platelet activation, signaling and aggregation—ALB—acquired immunodeficiency syndrome	0.000102	0.00213	CbGpPWpGaD
Alprostadil—PTGER2—Signaling Pathways—CCR2—acquired immunodeficiency syndrome	9.65e-05	0.00201	CbGpPWpGaD
Alprostadil—PTGER2—Signaling Pathways—CXCR4—acquired immunodeficiency syndrome	9.07e-05	0.00189	CbGpPWpGaD
Alprostadil—PTGER2—Signaling Pathways—CXCL12—acquired immunodeficiency syndrome	9.07e-05	0.00189	CbGpPWpGaD
Alprostadil—PTGIR—Hemostasis—ALB—acquired immunodeficiency syndrome	8.83e-05	0.00184	CbGpPWpGaD
Alprostadil—PTGIR—GPCR downstream signaling—CCL5—acquired immunodeficiency syndrome	8.69e-05	0.00181	CbGpPWpGaD
Alprostadil—PTGER1—GPCR downstream signaling—CCL5—acquired immunodeficiency syndrome	8.69e-05	0.00181	CbGpPWpGaD
Alprostadil—PTGER1—GPCR downstream signaling—CSF2—acquired immunodeficiency syndrome	8.56e-05	0.00179	CbGpPWpGaD
Alprostadil—PTGIR—GPCR downstream signaling—CSF2—acquired immunodeficiency syndrome	8.56e-05	0.00179	CbGpPWpGaD
Alprostadil—PTGER1—Gastrin-CREB signalling pathway via PKC and MAPK—IL6—acquired immunodeficiency syndrome	8.34e-05	0.00174	CbGpPWpGaD
Alprostadil—ABCC4—Platelet activation, signaling and aggregation—IL2—acquired immunodeficiency syndrome	8.28e-05	0.00173	CbGpPWpGaD
Alprostadil—ABCC4—Hemostasis—CSF2—acquired immunodeficiency syndrome	8.07e-05	0.00168	CbGpPWpGaD
Alprostadil—PTGIR—Signaling by GPCR—CCL5—acquired immunodeficiency syndrome	7.89e-05	0.00165	CbGpPWpGaD
Alprostadil—PTGER1—Signaling by GPCR—CCL5—acquired immunodeficiency syndrome	7.89e-05	0.00165	CbGpPWpGaD
Alprostadil—PTGIR—GPCR downstream signaling—CCR5—acquired immunodeficiency syndrome	7.83e-05	0.00163	CbGpPWpGaD
Alprostadil—PTGER1—GPCR downstream signaling—CCR5—acquired immunodeficiency syndrome	7.83e-05	0.00163	CbGpPWpGaD
Alprostadil—PTGIR—Signaling by GPCR—CSF2—acquired immunodeficiency syndrome	7.77e-05	0.00162	CbGpPWpGaD
Alprostadil—PTGER1—Signaling by GPCR—CSF2—acquired immunodeficiency syndrome	7.77e-05	0.00162	CbGpPWpGaD
Alprostadil—ABCC5—Disease—CXCR4—acquired immunodeficiency syndrome	7.52e-05	0.00157	CbGpPWpGaD
Alprostadil—PTGIR—Signaling Pathways—CCL3—acquired immunodeficiency syndrome	7.21e-05	0.0015	CbGpPWpGaD
Alprostadil—PTGER1—Signaling Pathways—CCL3—acquired immunodeficiency syndrome	7.21e-05	0.0015	CbGpPWpGaD
Alprostadil—PTGIR—Hemostasis—IL2—acquired immunodeficiency syndrome	7.16e-05	0.00149	CbGpPWpGaD
Alprostadil—PTGIR—Signaling by GPCR—CCR5—acquired immunodeficiency syndrome	7.11e-05	0.00148	CbGpPWpGaD
Alprostadil—PTGER1—Signaling by GPCR—CCR5—acquired immunodeficiency syndrome	7.11e-05	0.00148	CbGpPWpGaD
Alprostadil—PTGER2—Signaling Pathways—CCL5—acquired immunodeficiency syndrome	6.9e-05	0.00144	CbGpPWpGaD
Alprostadil—SLCO2B1—Transmembrane transport of small molecules—ALB—acquired immunodeficiency syndrome	6.87e-05	0.00143	CbGpPWpGaD
Alprostadil—PTGER2—Signaling Pathways—CSF2—acquired immunodeficiency syndrome	6.8e-05	0.00142	CbGpPWpGaD
Alprostadil—PTGER2—GPCR downstream signaling—IL2—acquired immunodeficiency syndrome	6.7e-05	0.0014	CbGpPWpGaD
Alprostadil—ABCC5—Transmembrane transport of small molecules—ALB—acquired immunodeficiency syndrome	6.57e-05	0.00137	CbGpPWpGaD
Alprostadil—PTGIR—Signaling Pathways—CCR2—acquired immunodeficiency syndrome	6.52e-05	0.00136	CbGpPWpGaD
Alprostadil—PTGER1—Signaling Pathways—CCR2—acquired immunodeficiency syndrome	6.52e-05	0.00136	CbGpPWpGaD
Alprostadil—PTGER2—Signaling Pathways—CCR5—acquired immunodeficiency syndrome	6.22e-05	0.0013	CbGpPWpGaD
Alprostadil—PTGIR—Signaling Pathways—CXCR4—acquired immunodeficiency syndrome	6.13e-05	0.00128	CbGpPWpGaD
Alprostadil—PTGER1—Signaling Pathways—CXCL12—acquired immunodeficiency syndrome	6.13e-05	0.00128	CbGpPWpGaD
Alprostadil—PTGIR—Signaling Pathways—CXCL12—acquired immunodeficiency syndrome	6.13e-05	0.00128	CbGpPWpGaD
Alprostadil—PTGER1—Signaling Pathways—CXCR4—acquired immunodeficiency syndrome	6.13e-05	0.00128	CbGpPWpGaD
Alprostadil—PTGER2—Signaling by GPCR—IL2—acquired immunodeficiency syndrome	6.08e-05	0.00127	CbGpPWpGaD
Alprostadil—ABCC4—Hemostasis—ALB—acquired immunodeficiency syndrome	5.26e-05	0.0011	CbGpPWpGaD
Alprostadil—ABCC5—Disease—CCR5—acquired immunodeficiency syndrome	5.16e-05	0.00108	CbGpPWpGaD
Alprostadil—PTGER1—Signaling Pathways—CCL5—acquired immunodeficiency syndrome	4.66e-05	0.000973	CbGpPWpGaD
Alprostadil—PTGIR—Signaling Pathways—CCL5—acquired immunodeficiency syndrome	4.66e-05	0.000973	CbGpPWpGaD
Alprostadil—PTGER1—Signaling Pathways—CSF2—acquired immunodeficiency syndrome	4.59e-05	0.000958	CbGpPWpGaD
Alprostadil—PTGIR—Signaling Pathways—CSF2—acquired immunodeficiency syndrome	4.59e-05	0.000958	CbGpPWpGaD
Alprostadil—ABCC4—Transmembrane transport of small molecules—ALB—acquired immunodeficiency syndrome	4.55e-05	0.00095	CbGpPWpGaD
Alprostadil—PTGIR—GPCR downstream signaling—IL2—acquired immunodeficiency syndrome	4.52e-05	0.000944	CbGpPWpGaD
Alprostadil—PTGER1—GPCR downstream signaling—IL2—acquired immunodeficiency syndrome	4.52e-05	0.000944	CbGpPWpGaD
Alprostadil—ABCC4—Hemostasis—IL2—acquired immunodeficiency syndrome	4.27e-05	0.00089	CbGpPWpGaD
Alprostadil—PTGIR—Signaling Pathways—CCR5—acquired immunodeficiency syndrome	4.2e-05	0.000876	CbGpPWpGaD
Alprostadil—PTGER1—Signaling Pathways—CCR5—acquired immunodeficiency syndrome	4.2e-05	0.000876	CbGpPWpGaD
Alprostadil—PTGIR—Signaling by GPCR—IL2—acquired immunodeficiency syndrome	4.11e-05	0.000857	CbGpPWpGaD
Alprostadil—PTGER1—Signaling by GPCR—IL2—acquired immunodeficiency syndrome	4.11e-05	0.000857	CbGpPWpGaD
Alprostadil—PTGER2—Signaling Pathways—IL2—acquired immunodeficiency syndrome	3.59e-05	0.00075	CbGpPWpGaD
Alprostadil—PTGER2—Signaling by GPCR—IL6—acquired immunodeficiency syndrome	3.57e-05	0.000746	CbGpPWpGaD
Alprostadil—ABCC5—Disease—CD4—acquired immunodeficiency syndrome	3.24e-05	0.000676	CbGpPWpGaD
Alprostadil—ABCC5—Metabolism—ALB—acquired immunodeficiency syndrome	3.08e-05	0.000642	CbGpPWpGaD
Alprostadil—PTGIR—Signaling Pathways—IL2—acquired immunodeficiency syndrome	2.43e-05	0.000506	CbGpPWpGaD
Alprostadil—PTGER1—Signaling Pathways—IL2—acquired immunodeficiency syndrome	2.43e-05	0.000506	CbGpPWpGaD
Alprostadil—PTGIR—Signaling by GPCR—IL6—acquired immunodeficiency syndrome	2.41e-05	0.000504	CbGpPWpGaD
Alprostadil—PTGER1—Signaling by GPCR—IL6—acquired immunodeficiency syndrome	2.41e-05	0.000504	CbGpPWpGaD
Alprostadil—PTGER2—Signaling Pathways—IL6—acquired immunodeficiency syndrome	2.11e-05	0.000441	CbGpPWpGaD
Alprostadil—ABCC5—Disease—IL6—acquired immunodeficiency syndrome	1.75e-05	0.000366	CbGpPWpGaD
Alprostadil—PTGIR—Signaling Pathways—IL6—acquired immunodeficiency syndrome	1.43e-05	0.000298	CbGpPWpGaD
Alprostadil—PTGER1—Signaling Pathways—IL6—acquired immunodeficiency syndrome	1.43e-05	0.000298	CbGpPWpGaD
